2024-07-31 15:38:07 ET
Summary
- UK-based Pharma giant GSK plc reported its Q2 earnings earlier today.
- GSK plc exceeded Q2 2024 expectations with revenue up 13%, operating profit up 18%, and EPS up 17%.
- GSK upgraded full-year guidance with 7-9% top-line growth forecasts, >10% growth in operating profit, and >10% EPS growth.
- Despite vaccine challenges and Zantac litigation, GSK's strong performance and growth opportunities make it undervalued with potential upside.
Investment Overview
I last covered GSK plc ( GSK ), the United Kingdom headquartered Pharma giant, in a note published almost exactly one year ago, reviewing the Pharma's Q2 2023 earnings.
GSK exceeded analysts' expectations that quarter and I gave its stock a "Buy" rating. One year on, the share price is up 7%, or 11% on a total return basis, and Q2 2024 earnings have just been released, so this feels like the right time to provide an update to my thesis....
Read the full article on Seeking Alpha
For further details see:
GSK Q2 Earnings Review: Vaccine Issues Aside, A Strong Quarter